Skip to content
Skip to footer
Company
Executive Team
Board Of Directors
Innovation
News
Investors
Shareholder Information
Stock Quote & Chart
Financial Filings
Shareholder Structure & History
Prospectus
Shareholder Meetings
Analyst Coverage
Transparency Notifications
Conversion Table
Corporate Governance
Overview
Board of Directors
Management
News
Events
IR Contact
Contact Us
EN
NL
FR
Close
Company
Executive Team
Board Of Directors
Innovation
News
Investors
Shareholder Information
Stock Quote & Chart
Financial Filings
Shareholder Structure & History
Prospectus
Shareholder Meetings
Analyst Coverage
Transparency Notifications
Conversion Table
Corporate Governance
Overview
Board of Directors
Management
News
Events
IR Contact
Contact Us
EN
NL
FR
General
News
ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)
July 19, 2018
EN
Login
Register
Username
Password
Forgot password?
Remember me
